Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 74-77, 2013.
Article
in English
| WPRIM
| ID: wpr-213728
ABSTRACT
Pemetrexed is approved as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with cisplatin and as a single agent for second-line treatment or for patients who show no disease progression after four cycles of platinum-based doublet induction chemotherapy as maintenance therapy. Pemetrexed has a modest toxicity profile and has not traditionally been regarded as a cause of interstitial pneumonitis. Here, we report on a rare case of pemetrexed-induced pneumonitis in a patient with NSCLC.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pneumonia
/
Adenocarcinoma
/
Cisplatin
/
Lung Diseases, Interstitial
/
Carcinoma, Non-Small-Cell Lung
/
Disease Progression
/
Induction Chemotherapy
/
Pemetrexed
/
Glutamates
/
Guanine
Limits:
Humans
Language:
English
Journal:
Cancer Research and Treatment
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS